Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial
APHINITY试验评估了帕妥珠单抗联合曲妥珠单抗双重抗HER2阻断治疗早期HER2阳性乳腺癌的心脏安全性
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2022.100772
de Azambuja, E; Agostinetto, E; Procter, M; Eiger, D; Pondé, N; Guillaume, S; Parlier, D; Lambertini, M; Desmet, A; Caballero, C; Aguila, C; Jerusalem, G; Walshe, J M; Frank, E; Bines, J; Loibl, S; Piccart-Gebhart, M; Ewer, M S; Dent, S; Plummer, C; Suter, T
